Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Area of interest

Area of interest

Type

Type

Guidance programme 1 selected

Guidance programme

Showing 91 to 100 of 875

TitleReference numberPublishedLast updated
Anhydrous sodium thiosulfate for preventing hearing loss caused by cisplatin chemotherapy in people 1 month to 17 years with localised solid tumoursTA1034
Vamorolone for treating Duchenne muscular dystrophy in people 4 years and overTA1031
Bimekizumab for treating moderate to severe hidradenitis suppurativa (terminated appraisal)TA1028
Andexanet alfa for reversing anticoagulation in people with intracranial haemorrhage (terminated appraisal)TA1029
Durvalumab with chemotherapy before surgery (neoadjuvant) then alone after surgery (adjuvant) for treating resectable non-small-cell lung cancerTA1030
Andexanet alfa for reversing anticoagulation from apixaban or rivaroxabanTA697
Tebentafusp for treating advanced uveal melanomaTA1027
Ublituximab for treating relapsing multiple sclerosisTA1025
Elranatamab for treating relapsed and refractory multiple myeloma after 3 or more treatmentsTA1023
Toripalimab with chemotherapy for untreated advanced oesophageal squamous cell cancer (terminated appraisal)TA1024

Results per page

  1. 10
  2. 25
  3. 50
  4. All